154 related articles for article (PubMed ID: 38662757)
1. Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma.
Ji Z; Zhang C; Yuan J; He Q; Zhang X; Yang D; Xu N; Chu J
PLoS One; 2024; 19(4):e0298775. PubMed ID: 38662757
[TBL] [Abstract][Full Text] [Related]
2. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
Wang L; Wang Q; Li Y; Qi X; Fan X
J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of N
Zhu HX; Lu WJ; Zhu WP; Yu S
J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
[TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma.
Tu K; Li J; Mo H; Xian Y; Xu Q; Xiao X
Int J Med Sci; 2021; 18(9):2030-2041. PubMed ID: 33850474
[TBL] [Abstract][Full Text] [Related]
6. The sorafenib resistance-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.
Luo T; Chen X; Pan W; Zhang S; Huang J
Cell Cycle; 2024 Jan; 23(2):150-168. PubMed ID: 38444181
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
[TBL] [Abstract][Full Text] [Related]
8. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
9. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.
Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D
Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373
[TBL] [Abstract][Full Text] [Related]
10. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer.
Xu X; Wang J
Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261
[TBL] [Abstract][Full Text] [Related]
11. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
12. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.
Wang J; Huang Z; Lu H; Zhang R; Feng Q; He A
Comput Math Methods Med; 2022; 2022():1258480. PubMed ID: 35242200
[TBL] [Abstract][Full Text] [Related]
13. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
14. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
15. A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma.
Chen Z; Zou Y; Zhang Y; Chen Z; Wu F; Jin H; Shi N
Dis Markers; 2022; 2022():8109771. PubMed ID: 35047095
[TBL] [Abstract][Full Text] [Related]
16. A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma.
Chen Z; Zou Y; Zhang Y; Chen Z; Wu F; Shi N; Jin H
J Clin Lab Anal; 2021 Nov; 35(11):e24005. PubMed ID: 34523732
[TBL] [Abstract][Full Text] [Related]
17. Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma.
Zhou X; Liu C; Zeng H; Wu D; Liu L
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33835133
[TBL] [Abstract][Full Text] [Related]
18. Prognostic analysis of
Li D; Fan X; Zuo L; Wu X; Wu Y; Zhang Y; Zou F; Sun Z; Zhang W
Ann Transl Med; 2022 Dec; 10(24):1356. PubMed ID: 36660710
[TBL] [Abstract][Full Text] [Related]
19. A prognostic signature established based on genes related to tumor microenvironment for patients with hepatocellular carcinoma.
Cui Z; Li G; Shi Y; Zhao X; Wang J; Hu S; Chen C; Li G
Aging (Albany NY); 2024 Apr; 16(7):6537-6549. PubMed ID: 38579170
[TBL] [Abstract][Full Text] [Related]
20. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.
Deng M; Lin JB; Zhao RC; Li SH; Lin WP; Zou JW; Wei W; Guo RP
BMC Cancer; 2021 Dec; 21(1):1347. PubMed ID: 34923955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
